Name | Title | Contact Details |
---|---|---|
Heidi Yernberg |
Managing Director and Chief Privacy Officer | Profile |
Charriet Womble |
Director of Regulatory Compliance | Profile |
Kelly Scoggins |
Director of Ethics and Compliance | Profile |
Alicia Oliver |
Vice President, Deputy General Counsel and Interim Chief Privacy Officer | Profile |
Eric Setterlund |
Associate General Counsel | Profile |
Skypoint Recovery is a substance abuse treatment center located in Akron, Ohio that offers a wide range of recovery services and treatment levels.
Sandra Heath & Associates is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Siemens Healthineers is the separately managed healthcare business of Siemens AG enabling healthcare providers worldwide to meet their current challenges and to excel in their respective environments. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. To help customers succeed in today`s dynamic healthcare marketplace, Siemens Healthineers is championing new business models that maximize opportunity and minimize risk for healthcare providers.
Shields Nursing Center - El Cerrito is a El Cerrito, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.